{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/CLDX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-18T15:52:08.829Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9507,"canonical_name":"Celldex Therapeutics, Inc.","cik":"0000744218","uei":null,"lei":null,"duns":null,"ticker":"CLDX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":8,"clinical":2},"count":10,"timeline":[{"ts":"2026-09-22","kind":"sec.filing","form_type":"8-K","title":"8-K — Celldex Therapeutics, Inc. — 2026-09-22","url_slug":"/sec/cik-0000744218/8-k/0001104659-26-109465","accession_number":"0001104659-26-109465","importance":35},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Celldex Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0000744218/schedule-13g/0000080255-26-000537","accession_number":"0000080255-26-000537","importance":55},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Celldex Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0000744218/10-q/0001104659-26-091984","accession_number":"0001104659-26-091984","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Celldex Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0000744218/8-k/0001171843-26-005316","accession_number":"0001171843-26-005316","importance":35},{"ts":"2026-07-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Celldex Therapeutics, Inc. — 2026-07-15","url_slug":"/sec/cik-0000744218/8-k/0001104659-26-083880","accession_number":"0001104659-26-083880","importance":35},{"ts":"2026-06-29","kind":"sec.filing","form_type":"4","title":"4 — Brownlie Keith L — 2026-06-29","url_slug":"/sec/cik-0001518575/4/0001518575-26-000002","accession_number":"0001518575-26-000002","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"8-K","title":"8-K — Celldex Therapeutics, Inc. — 2026-06-26","url_slug":"/sec/cik-0000744218/8-k/0001104659-26-078023","accession_number":"0001104659-26-078023","importance":35},{"ts":"2026-06-26","kind":"sec.filing","form_type":"S-8","title":"S-8 — Celldex Therapeutics, Inc. — 2026-06-26","url_slug":"/sec/cik-0000744218/s-8/0001104659-26-078233","accession_number":"0001104659-26-078233","importance":30},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Celldex Therapeutics","title":"A Phase I Study of CDX-622","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT06650761","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Celldex Therapeutics","title":"Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07256392","excerpt":"[\"Chronic Spontaneous Urticaria\"]","importance":60}]}